
Medicine and Health
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial
K. Shitara, Y. Bang, et al.
Trastuzumab deruxtecan (T-DXd) has shown promising clinical advancements for patients with HER2+ gastric cancer, according to the DESTINY-Gastric01 trial. Engaging explorations into HER2 biomarkers and resistance mechanisms highlight correlations that could shape future therapies. This vital research was led by an exceptional team of authors.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.